US health officials have agreed to allow emergency use of a second antibody drug to help the immune system fight Covid-19, an experimental medicine that President Donald Trump was given when he was sickened last month.
The Food and Drug Administration (FDA) authorised use of the Regeneron Pharmaceuticals Inc drug to try to prevent hospitalisation and worsening disease from developing in patients with mild-to-moderate symptoms.
The drug is given as a one-time treatment through an IV.
The FDA allowed its use in adults and children 12 and over who weigh at least 40 kilograms and who are at high risk of severe illness from Covid-19 because of age or certain other medical conditions.
READ MORE: Covid in Scotland: 'No plans' to make vaccine compulsory
Emergency authorisation allows the use of the drug to start while studies are continuing to establish safety and effectiveness.
Early results suggest the drug may reduce Covid-19-related hospitalisation or emergency room visits in patients at high risk for disease progression, the FDA said.
Regeneron said that initial doses will be made available to roughly 300,000 patients through a federal government allocation program. Those patients will not be charged for the drug but may have to pay part of the cost of giving the IV.
Initial supplies will likely be vastly outstripped by demand as the US has surged past 12 million reported cases, with the country facing what health experts say will be a dark winter due to uncontrolled spread of the virus.
There is no way to know whether the Regeneron drug helped Trump recover; he received a host of treatments and most Covid-19 patients recover on their own.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here